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554a Tuesday, February 23, 2010the dobutamine effects on preload recruitable stroke work and maximal systolic
elastance were significantly blunted in the mutant groups. Maximal exercise ca-
pacity of Wt rats was significantly longer than that of Hm. Electrophoretic my-
osin heavy chain analysis of left ventricle (LV) samples showed no differences
between Wt, Ht, or Hm in the beta myosin heavy chain proportions. Gene ex-
pression patterns in LVwere conductedwithAffymetrixGeneChipRat Genome
230 2.0microarrays usingWT andHmLV at three developmental stages (day 1,
day 20 and day 49). A Student t-test with a p value cut-off of 0.05 and aminimum
1.5-fold change reveals changes in 372mutation-specific transcripts (188 known
and 96 un-annotated genes). A number of titin associated genes were up-regu-
lated (Myot, T-cap, DARP, FHL1), and this up-regulation was verified by
QPCR. Hierarchical clustering revealed gene expression patterns of Wt and
Hm LV were related to their titin protein gel pattern. Predefined pathways and
functional categories annotated by KEGG, Biocarta, and GO using the DAVID
bioinformatic resource indicated involvement of TGF Beta 2, CTGF-regulated
fibrosis, Trdn-Casq interaction-regulated RyR channel, and cAMP-dependent
pathways. Supported by NIH HL77196.
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Wehavepreviously reported (Shaffer et al. 2009. J.Biol.Chem.284:12318-27) that
theN-terminal fragmentC0-C2ofmyosin binding protein-C (MyBP-C) canbundle
actin, providing evidence for interaction of MyBP-C and actin. Neutron scattering
studies (Whitten et al. 2008. PNAS 105:18360-5) also demonstrated the formation
of ordered complexes of C0-C2 with actin, but these experiments were conducted
under conditions that stabilizedG-actin at reduced ionic strength andpH8.0.To test
whether C0-C2 also decorates F-actin at physiological ionic strength and pH, we
incubated C0-C2 (5 - 30 uM, in a buffer containing in mM: 180 KCl, 1 MgCl2, 1
EDTA, 1 DTT, 20 imidazole, at pH 7.4) with F-actin (5 uM) for 30 min and exam-
inednegatively-stained samplesof the solutionbyelectronmicroscopy (EM).Anal-
ysis of EM images revealed that C0-C2 bound to F-actin to form long helically-or-
dered complexes with a mean diameter of 16 nm. Fourier transforms indicated that
C0-C2 binds with the helical periodicity of actin with strong 1st and 6th layer lines.
The results provide evidence that the N-terminus of MyBP-C binds regularly to F-
actin. Supported by NIH 5SC1HL096017 (RWK) and NIH HL080367 (SPH).
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Mutations in cardiacmyosin binding proteinC (cMyBP-C) are a frequent cause of
hypertrophic cardiomyopathy (HCM), a major cause of sudden cardiac death and
heart failure. Mutations include single amino acid substitutions and premature
stop codons, but it is unclear whether dominant negative effects of mutant pro-
teins, depletion ofwild-type protein due to an affected allele (haploinsufficiency),
or aberrant protein processing/degradation leads to disease. To distinguish among
these possibilities, we investigated the sarcomeric localization and functional ef-
fects of a spontaneous cMyBP-C missense mutation in Maine Coon cats, a natu-
rally occurring feline model of HCM. Immunofluorescent localization using an
antibody specific for the A31P mutation showed that A31P cMyBP-Cwas incor-
porated into the sarcomeres of cats heterozygous and homozygous for the A31P
mutation with similar distribution patterns as wild-type cMyBP-C. However,
dominant negative effects due to incorporation of themutant protein were not ev-
ident because myofilament Ca2þ sensitivity of tension and rate of tension devel-
opment were not different in permeabilized myocytes from wild-type versus
A31P cats. Actin binding and in vitromotility experiments also showed no differ-
encebetweenwild-type andA31P recombinant felineC0C2proteins.By contrast,
cytosolic proteasomes from a homozygous cat showed elevated b-5 (chymotryp-
sin-like) proteolitic activity compared to wild-type or heterozygous cats. Addi-
tional experiments are necessary to determine whether aberrant protein degrada-
tion of A31P cMyBP-C contributes to disease. Supported by NIH HL080367.
2856-Pos
Force, Ca-Sensitivity and Contractile Efficiency in Human Myocardium
Expressing a Truncated Cardiac Myosin Binding Protein-C
Peter J. Griffiths1, Henrik Isackson2, Charles S. Redwood2, Hugh Watkins2,
Christopher C. Ashley1.
1Department of Physiology, Anatomy, and Genetics, Oxford University,
Oxford, United Kingdom, 2Department of Cardiovascular Medicine, Oxford
University, Oxford, United Kingdom.We have investigated contractile parameters of ventricular myocardium in
samples from a patient diagnosed with hypertrophic cardiomyopathy (HCM)
caused by a truncation mutation inMYBPC3, the gene encoding cardiac myosin
binding protein C (cMyBP-C). The mutation truncates the protein in the C7 do-
main resulting in the loss of 408 residues. Our earlier work has shown that the
truncated protein is not stably expressed and the disease is likely to be mediated
by cMyBP-C haploinsufficiency.
We measured Ca2þ-sensitivity, isometric force generation, and myosin ATPase
activity in tissue flash frozen in liquid nitrogen and subsequently stored in dry
ice at 80C before chemical demembranation. ATPase activity within the
myocardium was measured simultaneously with force, using a fluorimetric
technique and a linked-enzyme assay. Healthy human cardiac ventricular tissue
served as control.
The mutant tissue exhibited an increased Ca2þ-sensitivity (pCa50 in control:
5.9850.02 (n = 12); mutant: 6.5250.07 (n=6), p<0.001) whereas the maxi-
mum isometric tension was reduced in mutant compared to control (control:
18.553.0 kN.m2 (n = 26); mutant 8.650.8 kN.m2 (n=7), p<0.05). There
was no difference in the ATPase activity in maximally Ca2þ-activated tissue
between the two groups (control, 131520mM.s1 (n=26); mutant,
12759mM.s1 (n=7), p=0.87). The dependence of ATPase activity on force
was linear, with a slope (tension cost) of 7.3250.97mM.m2.kN1.s1 (mutant,
n=6) and 3.4650.87 mM. m2.kN1.s1 (control, n=10), p = 0.01. The increased
tension cost of the mutant sarcomeres may cause energetic compromise, which
has been suggested to play an important role in the development of the HCM
phenotype. Increased Ca2þsensitivity has been reported in other investigations
on HCM myocardium, and may be a direct effect of cMyBP-C haploinsuffi-
ciency or reflect compensatory changes.
Work supported by the British Heart Foundation.
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In skinned myocardium, cAMP-dependent protein kinase (PKA)-catalyzed
phosphorylation of cardiac myosin binding protein-C (cMyBP-C) and troponin
I (cTnI) leads to a decrease in myofilament Ca2þ-sensitivity and an acceleration
in the kinetics of cross-bridge cycling. To examine the relative roles of cTnI
and cMyBP-C phosphorylation in altering contractile function, we determined
the Ca2þ-sensitivity of force (pCa50) and the rate of force redevelopment (ktr)
in untreated and PKA-treated murine myocardium expressing: (1) phosphory-
latable cTnI and cMyBP-C (WT), (2) non-phosphorylatable cTnI with
serines23/24/43/45 and threonine144 residues mutated to alanines (cTnIala5), (3)
phosphorylatable cTnI on a cMyBP-C null background (cMyBP-C-/-), and
(4) non-phosphorylatable cTnI on a cMyBP-C null background (cTnIala5/
cMyBP-C-/-). A novel aspect of this study was the use of 2,3-Butandione Mon-
oxime (BDM) treatments to reduce the basal levels of myosin regulatory light
chain (RLC) phosphorylation to near zero in order to more accurately define the
functional consequences of removing cMyBP-C and/or cTnI phoshorylation in
transgenic myocardium. Our results showed that in the absence of RLC phos-
phorylation, PKA-treatment decreased pCa50 in WT, cTnIala5, and cMyBP-C
-/-
myocardium by 0.13, 0.08 and 0.09 pCa units, respectively, but had no effect in
cTnIala5/cMyBP-C
-/- myocardium. InWT and cTnIala5 myocardium, PKA treat-
ment increased ktr at submaximal levels of activation; however, treatment did
not have an effect on ktr in cMyBP-C
-/- and cTnIala5/cMyBP-C
-/- myocardium.
Together, these results indicate that the attenuation of the myofilament force
response following PKA treatment is due to phosphorylation of both cTnI
and cMyBP-C and that the reduced Ca2þ-sensitivity of force mediated by phos-
phorylation of cMyBP-C is most likely due to an increased rate constant of
cross-bridge detachment that also contributes to an acceleration of cross-bridge
cycling kinetics.
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The effect of endothelin, a powerful vasoconstrictor and enhancer of cardiac
contractility, and hypoxia on the degree of phosphorylation of cardiac myosin
binding protein C (cMyBP-C) has been studied in cardiac trabeculae isolated
from rat hearts. Endothelin in concentrations that increase contractility increases
phosphorylation in a dose-dependent fashion. Increase in sarcomere length
itself increases phosphorylation and enhances the effect of endothelin on phos-
phorylation. Hypoxia decreases phosphorylation in a duration-dependent
